Alltrna expands leadership team

Flagship Pioneering company Alltrna, which is unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, has appointed Chris Henderson, as chief scientific officer and promoted William (Will) Kiesman, to the post of chief technology officer.

Dr Henderson was formerly senior vice president, head of research at US biotech major Biogen (Nasdaq: BIIB). In this role at Biogen, Dr Henderson led a team responsible for pre-clinical programs and target validation across the company's core disease areas of neurodegenerative diseases, multiple sclerosis and immunology, neuromuscular and muscle diseases, ophthalmology, and genetic and neurodevelopmental disorders.

Prior to the promotion, Dr Kiesman was SVP, CMC and Medicinal Chemistry at Alltrna. At Alltrna, he has led the build of the company's internal medicinal and computational chemistry capabilities, driven the design and construction of critical lab infrastructure, and assembled an end-to-end tRNA process development and manufacturing team.